Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 16
2022 42
2023 30
2024 32
2025 16
2026 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

129 results

Results by year

Filters applied: . Clear all
Page 1
Contemporary perspectives on heterotopic ossification.
Hwang CD, Pagani CA, Nunez JH, Cherief M, Qin Q, Gomez-Salazar M, Kadaikal B, Kang H, Chowdary AR, Patel N, James AW, Levi B. Hwang CD, et al. JCI Insight. 2022 Jul 22;7(14):e158996. doi: 10.1172/jci.insight.158996. JCI Insight. 2022. PMID: 35866484 Free PMC article. Review.
Heterotopic ossification (HO) is the formation of ectopic bone that is primarily genetically driven (fibrodysplasia ossificans progressiva [FOP]) or acquired in the setting of trauma (tHO). HO has undergone intense investigation, especially over the last 50 y …
Heterotopic ossification (HO) is the formation of ectopic bone that is primarily genetically driven (fibrodysplasia ossificans …
Palovarotene: First Approval.
Hoy SM. Hoy SM. Drugs. 2022 Apr;82(6):711-716. doi: 10.1007/s40265-022-01709-z. Drugs. 2022. PMID: 35384641 Review.
Palovarotene (Sohonos ) is an orally bioavailable selective retinoic acid receptor (RAR)gamma agonist being developed by Ipsen for the reduction of heterotopic ossification (HO) formation in patients with fibrodysplasia ossificans progressiva (FOP). By bindin …
Palovarotene (Sohonos ) is an orally bioavailable selective retinoic acid receptor (RAR)gamma agonist being developed by Ipsen for the reduc …
Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial.
Di Rocco M, Forleo-Neto E, Pignolo RJ, Keen R, Orcel P, Funck-Brentano T, Roux C, Kolta S, Madeo A, Bubbear JS, Tabarkiewicz J, Szczepanek M, Bachiller-Corral J, Cheung AM, Dahir KM, Botman E, Raijmakers PG, Al Mukaddam M, Tile L, Portal-Celhay C, Sarkar N, Hou P, Musser BJ, Boyapati A, Mohammadi K, Mellis SJ, Rankin AJ, Economides AN, Trotter DG, Herman GA, O'Meara SJ, DelGizzi R, Weinreich DM, Yancopoulos GD, Eekhoff EMW, Kaplan FS. Di Rocco M, et al. Nat Med. 2023 Oct;29(10):2615-2624. doi: 10.1038/s41591-023-02561-8. Epub 2023 Sep 28. Nat Med. 2023. PMID: 37770652 Free PMC article. Clinical Trial.
Fibrodysplasia ossificans progressiva (FOP) is a rare disease characterized by heterotopic ossification (HO) in connective tissues and painful flare-ups. ...
Fibrodysplasia ossificans progressiva (FOP) is a rare disease characterized by heterotopic ossification (HO) in connect …
Fibrodysplasia Ossificans Progressiva.
Acosta CES, Fernández ER. Acosta CES, et al. J Clin Rheumatol. 2021 Dec 1;27(8S):S858. doi: 10.1097/RHU.0000000000000494. J Clin Rheumatol. 2021. PMID: 35073643 No abstract available.
Immunologic Aspects in Fibrodysplasia Ossificans Progressiva.
Diolintzi A, Pervin MS, Hsiao EC. Diolintzi A, et al. Biomolecules. 2024 Mar 16;14(3):357. doi: 10.3390/biom14030357. Biomolecules. 2024. PMID: 38540775 Free PMC article. Review.
PURPOSE OF REVIEW: This review will examine recent findings on the roles of inflammation and the immune system in fibrodysplasia ossificans progressiva (FOP). FOP is a genetic condition of aggressive and progressive HO formation. ...
PURPOSE OF REVIEW: This review will examine recent findings on the roles of inflammation and the immune system in fibrodysplasia o …
Cell Senescence in Heterotopic Ossification.
Pignolo RJ, Kaplan FS, Wang H. Pignolo RJ, et al. Biomolecules. 2024 Apr 16;14(4):485. doi: 10.3390/biom14040485. Biomolecules. 2024. PMID: 38672501 Free PMC article. Review.
The formation of bone outside the normal skeleton, or heterotopic ossification (HO), occurs through genetic and acquired mechanisms. Fibrodysplasia ossificans progressiva (FOP), the most devastating genetic condition of HO, is due to mutations in the ACVR1/AL …
The formation of bone outside the normal skeleton, or heterotopic ossification (HO), occurs through genetic and acquired mechanisms. Fibr …
Fibrodysplasia ossificans progressiva emerges from obscurity.
Kaplan FS, Shore EM, Pignolo RJ. Kaplan FS, et al. Trends Mol Med. 2025 Feb;31(2):106-116. doi: 10.1016/j.molmed.2024.08.010. Epub 2024 Sep 18. Trends Mol Med. 2025. PMID: 39299836 Review.
Fibrodysplasia ossificans progressiva (FOP), a disorder of congenital skeletal malformations and progressive extraskeletal ossification, is the most severe form of heterotopic ossification (HO) in humans. ...
Fibrodysplasia ossificans progressiva (FOP), a disorder of congenital skeletal malformations and progressive extraskele …
How Activin A Became a Therapeutic Target in Fibrodysplasia Ossificans Progressiva.
Srinivasan D, Arostegui M, Goebel EJ, Hart KN, Aykul S, Lees-Shepard JB, Idone V, Hatsell SJ, Economides AN. Srinivasan D, et al. Biomolecules. 2024 Jan 12;14(1):101. doi: 10.3390/biom14010101. Biomolecules. 2024. PMID: 38254701 Free PMC article. Review.
Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disorder characterized by episodic yet cumulative heterotopic ossification (HO) of skeletal muscles, tendons, ligaments, and fascia. ...
Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disorder characterized by episodic yet cumulative heterot …
Primary cilia mediate skeletogenic BMP and Hedgehog signaling in heterotopic ossification.
He K, Jiang H, Li W, Toutounchi S, Huang Y, Wu J, Ma X, Baehr W, Pignolo RJ, Ling K, Zhou X, Wang H, Hu J. He K, et al. Sci Transl Med. 2024 Jul 24;16(757):eabn3486. doi: 10.1126/scitranslmed.abn3486. Epub 2024 Jul 24. Sci Transl Med. 2024. PMID: 39047114
Heterotopic ossification (HO), defined as the formation of extraskeletal bone in muscle and soft tissues, is a diverse pathological process caused by either genetic mutations or inciting trauma. Fibrodysplasia ossificans progressiva (FOP) is a genetic form of …
Heterotopic ossification (HO), defined as the formation of extraskeletal bone in muscle and soft tissues, is a diverse pathological process …
Intersections of Fibrodysplasia Ossificans Progressiva and Traumatic Heterotopic Ossification.
Juan C, Bancroft AC, Choi JH, Nunez JH, Pagani CA, Lin YS, Hsiao EC, Levi B. Juan C, et al. Biomolecules. 2024 Mar 14;14(3):349. doi: 10.3390/biom14030349. Biomolecules. 2024. PMID: 38540768 Free PMC article. Review.
HO can develop as a consequence of traumatic insult or as a result of dysregulated osteogenic signaling, as in the case of the orphan disease fibrodysplasia ossificans progressiva (FOP). Traumatic HO (tHO) formation is mediated by the complex interplay of sig …
HO can develop as a consequence of traumatic insult or as a result of dysregulated osteogenic signaling, as in the case of the orphan diseas …
129 results